Article
Oncology
Jingjing Miao, Lin Wang, Sze Huey Tan, Jin-Gao Li, Junlin Yi, Enya H. W. Ong, Laura L. Y. Tan, Ye Zhang, Xiaochang Gong, Qiuyan Chen, Yan-Qun Xiang, Ming-Yuan Chen, Ying Guo, Xing Lv, Wei-Xiong Xia, Linquan Tang, Xiaowu Deng, Xiang Guo, Fei Han, Hai-Qiang Mai, Melvin L. K. Chua, Chong Zhao
Summary: In this randomized clinical trial, adjuvant capecitabine at the full dose following CCRT was well tolerated and improved failure-free survival among patients with LA-NPC and high-risk factors. Further investigations assessing optimal dose and duration are warranted.
Article
Oncology
Rui Zou, Jing-Jing Yuan, Qiang Li, Jian-Wu Ding, Bing Liao, Zi-Wei Tu, Rong-Huan Hu, Dan Gong, Jia-Li Hu, Lei Zeng
Summary: The study analyzed the outcomes and toxicities of ICT followed by CCRT plus ACT in LA-NPC patients, and found that this treatment approach did not significantly improve DFS and OS compared to adding ICT to CCRT, with more acute adverse events. Longer-term clinical studies are needed to evaluate treatment outcomes and late toxicities.
FRONTIERS IN ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Mu-Hung Tsai, Shang-Yin Wu, Hsi-Huei Lu, Tsung Yu, Sen-Tien Tsai, Yuan-Hua Wu
Summary: Adjuvant chemotherapy improves overall survival and decreases the risk of distant metastasis in high-risk N3 nasopharyngeal carcinoma patients.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Hao-Yun Tao, Hui Liu, Fang He, Cai-Xian He, Ran Li, Kun-Peng Du, Ya-Wei Yuan, Rong-Hui Zheng
Summary: This study showed that for N2-3 positive LANC, ACT following ICT plus CCRT can reduce distant metastasis and improve overall survival and disease-free survival.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Article
Oncology
Kequan Chen, Guoding Xu, Yong Liang, Ping Liang, Weiwei Gao, Zhou Li, Weichao Liang, Zheng Tao, Jiaxin Chen, Xiaohua Hu, Yaocan Xu
Summary: This study aimed to assess the safety and effectiveness of concurrent chemoradiotherapy (CCRT) combined with anlotinib in patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC). The results showed that the complete response rates in the CCRT + anlotinib arm at 1 week, 3 months, and 6 months post-radiotherapy were 60.0%, 91.4%, and 97.1%, respectively, compared with 40.5%, 81.1%, and 91.9% in the CCRT arm, but there was no significant difference. The preliminary results of this study suggest that CCRT + anlotinib has acceptable toxicity profiles, good compliance, and promising therapeutic effectiveness in LA-NPC patients.
Article
Oncology
Hesong Shen, Jinxue Yin, Running Niu, Yanbang Lian, Yuanying Huang, Chunrong Tu, Daihong Liu, Xiaoxia Wang, Xiaosong Lan, Xiaoqian Yuan, Jiuquan Zhang
Summary: This study developed and validated a joint radiomic and clinical signature (RCS) to predict the prognosis of patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC) and identify potential treatment benefits. The RCS showed better predictive ability for 5-year progression-free survival compared to the TNM staging system. It provides a noninvasive way to predict outcomes and guide personalized treatment decisions.
RADIOTHERAPY AND ONCOLOGY
(2022)
Article
Cell Biology
Xiaoli Mu, Hongyan Liu, Juan Wu, Shi Chen, Xingchen Peng, Jingjing Wang, Zhigong Wei, Ling He, Jiyan Liu, Zejun Lu, Yonglin Su
Summary: In patients with locoregionally advanced nasopharyngeal carcinoma, induction chemotherapy plus concurrent chemoradiotherapy achieved comparable survival outcomes to concurrent chemoradiotherapy plus adjuvant chemotherapy with a lower incidence of toxicity.
Article
Oncology
Fangfang Kong, Guangsen Pan, Chengrun Du, Chaosu Hu, Hongmei Ying
Summary: For patients with negative post-IC EBV DNA, IC + RT displayed similar efficacy to IC + CCRT/AC in the treatment of LA-NPC, with fewer acute toxicities. This study suggests that the omission of concurrent or adjuvant chemotherapy may be feasible for these patients.
Article
Oncology
So Jung Lee, Yeon-Sil Kim, Chul Seung Kay, Myungsoo Kim, Jin Hyung Kang, Jae Ho Byun, Ji Hyung Hong
Summary: The study found that complete response one month after CCRT was a favorable prognosticator for progression-free survival (PFS) and overall survival (OS), and adjuvant chemotherapy (ACT) was also an independent factor for PFS and OS. Patients who achieved complete response after CCRT followed by ACT showed significantly better outcomes compared to other groups.
Article
Oncology
Qiulu Zhong, Danjing Luo, Xiangde Li, Qinghua Du, Qianfu Liang, Wenqi Liu, Jian Li, Xiaodong Zhu
Summary: This study aimed to evaluate the efficacy of adding induction chemotherapy or adjuvant chemotherapy to concurrent chemoradiotherapy in patients with T3-4N0-1M0 nasopharyngeal carcinoma. The study found that adding induction chemotherapy or adjuvant chemotherapy did not significantly improve the prognosis of these patients.
CANCER BIOLOGY & THERAPY
(2023)
Article
Oncology
Hao-Yun Tao, Fang He, Qi-Yun Shi, Ran Liu, Zhi-Long Wang, Kun-Peng Du, Jian-Feng Li, Hui Liu, Zhi-Qiang Lu, Jing-Jing Zhang, Yu-Hai Bai
Summary: This study aims to explore the clinical value of adjuvant chemotherapy or maintenance chemotherapy in patients with locally advanced nasopharyngeal carcinoma after induction chemotherapy and concurrent chemoradiotherapy. The results demonstrate that the addition of AC/MC can improve the distant metastasis-free survival and prolong the overall survival of high-risk patients.
Article
Oncology
Zhining Yang, Zeman Cai, Qingxin Cai, Yingji Hong, Cuidai Zhang, Kaichun Huang, Zhixiong Lin, Mei Li
Summary: The study compared the efficacy and safety of induction chemotherapy followed by intensity-modulated radiotherapy versus concurrent chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. The results showed similar outcomes in terms of PFS, OS, LRRFS, and DMFS between the two treatment arms, but the IC plus IMRT arm had lower incidences of leukopenia and anemia.
Article
Oncology
Danhui Weng, Huihua Xiong, Changkun Zhu, Xiaoyun Wan, Yaxia Chen, Xinyu Wang, Youzhong Zhang, Jie Jiang, Xi Zhang, Qinglei Gao, Gang Chen, Hui Xing, Changyu Wang, Kezhen Li, Yaheng Chen, Yuyan Mao, Dongxiao Hu, Zimin Pan, Qingqin Chen, Baoxia Cui, Kun Song, Cunjian Yi, Guangcai Peng, Xiaobing Han, Ruifang An, Liangsheng Fan, Wei Wang, Tingchuan Xiong, Yile Chen, Zhenzi Tang, Lin Li, Xingsheng Yang, Xiaodong Cheng, Weiguo Lu, Hui Wang, Beihua Kong, Xing Xie, Ding Ma
Summary: This study assessed the non-inferiority of adjuvant chemotherapy alone versus adjuvant concurrent chemoradiotherapy as an alternative strategy for patients with early-stage cervical cancer. The results showed that adjuvant chemotherapy alone had similar efficacy in terms of prognosis, adverse effects, and quality of life compared to adjuvant concurrent chemoradiotherapy.
FRONTIERS OF MEDICINE
(2023)
Article
Gastroenterology & Hepatology
Hyehyun Jeong, Kyu-pyo Kim, Jae Ho Jeong, Dae Wook Hwang, Jae Hoon Lee, Ki-Hun Kim, Deok-Bog Moon, Myung Ah Lee, Se Jun Park, Hong Jae Chon, Jin-hong Park, Ji Sung Lee, Baek-Yeol Ryoo, Changhoon Yoo
Summary: The effectiveness of adjuvant gemcitabine plus cisplatin (GemCis) therapy was evaluated in a homogeneous group of high-risk patients with resected, lymph node-positive extrahepatic cholangiocarcinoma. The study found that adjuvant GemCis did not improve survival outcomes compared with capecitabine in this patient population.
Article
Gastroenterology & Hepatology
Sundeep Singh Saluja, Phani Kumar Nekarakanti, Pramod Kumar Mishra, Anurita Srivastava, Kishore Singh
Summary: The study concluded that adjuvant GemCis therapy for 6 cycles does not improve disease-free survival (DFS) or overall survival (OS) compared to R0 surgery alone in patients with gallbladder carcinoma (GBC).
JOURNAL OF GASTROINTESTINAL SURGERY
(2022)
Article
Polymer Science
Tongtong Zhou, Tao Liu, Yu Bao, Ping Zhang, Casey Yan, Fujun Yao, Shuxun Cui, Yongming Chen, Xin Chen, You Yu
Article
Chemistry, Applied
Rui Zhang, Tianyun Li, Houbo Zhou, Huahua Huang, Yongming Chen
REACTIVE & FUNCTIONAL POLYMERS
(2018)
Article
Chemistry, Multidisciplinary
Zhiyu He, Zhijia Liu, Houkuan Tian, Yizong Hu, Lixin Liu, Kam W. Leong, Hai-Quan Mao, Yongming Chen
Article
Oncology
Xing-Li Yang, Yan Wang, Yong Bao, Shao-Bo Liang, Sha-Sha He, Dan-Ming Chen, Hai-Yang Chen, Li-Xia Lu, Yong Chen
Article
Chemistry, Physical
Dongmei Han, Yong Chen, Shuanjin Wang, Min Xiao, Yixin Lu, Yuezhong Meng
Article
Biochemistry & Molecular Biology
Lilong Sun, Zhijia Liu, Houkuan Tian, Zhicheng Le, Lixin Liu, Kam W. Leong, Hai-Quan Mao, Yongming Chen
Article
Chemistry, Physical
Boyuan Chen, Zhitao Hu, Haoqi Li, Zhiyong Li, Qiong Li, Yongming Chen
COLLOIDS AND SURFACES A-PHYSICOCHEMICAL AND ENGINEERING ASPECTS
(2019)
Review
Oncology
Run-Cong Nie, Fo-Ping Chen, Shu-Qiang Yuan, Ying-Shan Luo, Shi Chen, Yong-Ming Chen, Xiao-Jiang Chen, Ying-Bo Chen, Yuan-Fang Li, Zhi-Wei Zhou
EUROPEAN JOURNAL OF CANCER
(2019)
Article
Polymer Science
Jing Wang, Yan Lu, Yongming Chen
Article
Oncology
Shao-Bo Liang, Ning Zhang, Dan-Ming Chen, Xing-Li Yang, Bin-Hong Chen, Hai Zhao, Rui-Liang Lu, Yong Chen, Li-Wu Fu
RADIOTHERAPY AND ONCOLOGY
(2019)
Article
Engineering, Biomedical
Zhipeng Zeng, Cong Dong, Pengfei Zhao, Zhijia Liu, Lixin Liu, Hai-Quan Mao, Kam W. Leong, Xiaohu Gao, Yongming Chen
ADVANCED HEALTHCARE MATERIALS
(2019)
Article
Oncology
Ruiwan Chen, Yu Zhou, Yujie Yuan, Qun Zhang, Shasha He, Yong Chen, Yufeng Ren
FRONTIERS IN ONCOLOGY
(2019)
Article
Polymer Science
Yongwei Wu, Zhitao Hu, Huahua Huang, Yongming Chen
Article
Oncology
Jing Guo, Yongming Chen, Zhimin Liu, Yuanxiang Guan, Wei Wang, Xiaowei Sun, Wei Li, Dazhi Xu
Article
Polymer Science
Houbo Zhou, Christopher M. Plummer, Huaan Li, Huahua Huang, Pengfei Ma, Le Li, Lixin Liu, Yongming Chen